CompletedNCT03396588
Medication After Prenatal Opioid Exposure and Early Brain Development
About this title
Read the official source — NCT03396588Medication studyUp to 7 daysUnited StatesMental health
Understand this study
Who was this study for?
Listed age limits: up to 7 days.
- Listed locations
- LexingtonSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: December 7, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 120
- Sponsor
- Henrietta Bada
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 12 Hours to 7 Days
- Official registry ID
- NCT03396588
- Official title
Show the full official title
Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedLexington
Questions about this study
Who is behind this study?
The study sponsor is Henrietta Bada.
Did this study involve medication?
Yes. The study involved medication, including Clonidine and Morphine.
Who was this study for?
Listed age limits: up to 7 days.
Want to explore more studies?
Explore studiesRelated studies
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
Buprenorphine and naloxone for heroin dependence